The association of smoking and surgery in inflammatory bowel disease is modified by age at diagnosis

Clinical and Translational Gastroenterology

Volumn 7, Issue 4, 2016, Pages

  Frolkis, Alexandra D ^a   De Bruyn, Jennifer ^a   Jette, Nathalie ^a,b   Lowerison, Mark ^b   Engbers, Jordan ^a,b   Ghali, William ^a   Lewis, James ^c   Vallerand, Isabelle ^a,b   Patten, Scott ^a,b   Eksteen, Bertus ^a   Barnabe, Cheryl ^a   Panaccione, Remo ^a   Ghosh, Subrata ^a   Wiebe, Samuel ^a,b   Kaplan, Gilaad G ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; COLECTOMY; CROHN DISEASE; EX-SMOKER; FEMALE; HUMAN; INCIDENCE; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; NEVER SMOKER; RISK FACTOR; SENSITIVITY ANALYSIS; SMOKING; SMOKING CESSATION; SURGICAL RISK; ULCERATIVE COLITIS;

EID: 85006698335     PISSN: 2155384X     EISSN: None     Source Type: Journal    
DOI: 10.1038/ctg.2016.21     Document Type: Article

References (45)

1. Molodecky NA, Soon IS, Rabi DM et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46 54.e42; quiz e30.
2. Hazlewood GS, Rezaie A, Borman M et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: A network meta-Analysis. Gastroenterology 2015; 148: 344 54.e5.
3. Frolkis AD, Dykeman J, Negron ME et al. Risk of surgery for inflammatory bowel diseases has decreased over time: A systematic review and meta-Analysis of population-based studies. Gastroenterology 2013; 145: 996 1006.
4. Frolkis A, Dieleman LA, Barkema H et al. Environment and the inflammatory bowel diseases. Can J Gastroenterol 2013; 27: e18 e24.
5. Molodecky NA, Kaplan GG. Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol (NY) 2010; 6: 339 346.
6. Calkins BM. A meta-Analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci 1989; 34: 1841 1854.
7. Coward S, Heitman SJ, Clement F et al. Funding a smoking cessation program for Crohn's disease: An economic evaluation. Am J Gastroenterol 2015; 110: 368 377.
8. Miheller P, Kiss LS, Juhasz M et al. Recommendations for identifying Crohn's disease patients with poor prognosis. Exp Rev Clin Immunol 2013; 9: 65 75; quiz 6.
9. Sands BE, Arsenault JE, Rosen MJ et al. Risk of early surgery for Crohn's disease: implications for early treatment strategies. Am J Gastroenterol 2003; 98: 2712 2718.
10. Cottone M, Rosselli M, Orlando A et al. Smoking habits and recurrence in Crohn's disease. Gastroenterology 1994; 106: 643 648.
11. Nunes T, Etchevers MJ, Domenech E et al. Smoking does influence disease behaviour and impacts the need for therapy in Crohn's disease in the biologic era. Aliment Pharmacol Ther 2013; 38: 752 760.
12. Nunes T, Etchevers MJ, Merino O et al. Does smoking influence Crohn's disease in the biologic era? The TABACROHN study. Inflamm Bowel Dis 2013; 19: 23 29.
13. Lawrance IC, Murray K, Batman B et al. Crohn's disease and smoking: is it ever too late to quit? J Crohns Colitis 2013; 7: e665 e671.
14. Lakatos PL, Vegh Z, Lovasz BD et al. Is current smoking still an important environmental factor in inflammatory bowel diseases? Results from a population-based incident cohort. Inflamm Bowel Dis 2013; 19: 1010 1017.
15. Szamosi T, Banai J, Lakatos L et al. Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn's disease, while smoking decreases the risk of colectomy in ulcerative colitis. Eur J Gastroenterol Hepatol 2010; 22: 872 879.
16. Bastida G, Beltran B. Ulcerative colitis in smokers, non-smokers and ex-smokers. World J Gastroenterol 2011; 17: 2740 2747.
17. Health & Social Care Information Centre. Statistics on Smoking: England 2013. Available at www.hscic.gov.uk.
18. THIN Data Guide for Researchers version 2. 2010, pp. 106 108. Available at https://www.ucl.ac.uk/pcph/research-groups-Themes/thin-pub/database.
19. Wallace H, Shorvon S, Tallis R. Age-specific incidence and prevalence rates of treated epilepsy in an unselected population of 2, 052, 922 and age-specific fertility rates of women with epilepsy. Lancet 1998; 352: 1970 1973.
20. Bhayat F, Das-Gupta E, Smith C et al. The incidence of and mortality from leukaemias in the UK: A general population-based study. BMC Cancer 2009; 9: 252.
21. Atkinson TM, Halabi S, Bennett AV et al. Measurement of affective and activity pain interference using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903. Pain Med 2012; 13: 1417 1424.
22. Kronman MP, Zaoutis TE, Haynes K et al. Antibiotic exposure and IBD development among children: A population-based cohort study. Pediatrics 2012; 130: e794 e803.
23. Lewis JD, Brensinger C, Bilker WB et al. Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease. Pharmacoepidemiol Drug Saf 2002; 11: 211 218.
24. Lewis JD, Schinnar R, Bilker WB et al. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007; 16: 393 401.
25. Lewis JD, Bilker WB, Weinstein RB et al. The relationship between time since registration and measured incidence rates in the General Practice Research Database. Pharmacoepidemiol Drug Saf 2005; 14: 443 451.
26. Margolis DJ, Fanelli M, Hoffstad O et al. Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease. Am J Gastroenterol 2010; 105: 2610 2616.
27. Kaplan GG, Hubbard J, Korzenik J et al. The inflammatory bowel diseases and ambient air pollution: A novel association. Am J Gastroenterol 2010; 105: 2412 2419.
28. Lewis JD, Brensinger C. Agreement between GPRD smoking data: A survey of general practitioners and a population-based survey. Pharmacoepidemiol Drug Saf 2004; 13: 437 441.
29. Silverberg MS, Satsangi J, Ahmad T et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 MontrealWorld Congress of Gastroenterology. Can J Gastroenterol 2005; 19: 5A 36A.
30. Ramadas AV, Gunesh S, Thomas GA et al. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986 2003): A study of changes in medical treatment and surgical resection rates. Gut 2010; 59: 1200 1206.
31. Peyrin-Biroulet L, Harmsen WS, Tremaine WJ et al. Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota (1970 2004). Am J Gastroenterol 2012; 107: 1693 1701.
32. Picco MF, Zubiaurre I, Adluni M et al. Immunomodulators are associated with a lower risk of first surgery among patients with non-penetrating non-stricturing Crohn's disease. Am J Gastroenterol 2009; 104: 2754 2759.
33. Henriksen M, Jahnsen J, Lygren I et al. C-reactive protein: A predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective populationbased study. Gut 2008; 57: 1518 1523.
34. Poole CD, Conway P, Currie CJ. An evaluation of the association between C-reactive protein, the change in C-reactive protein over one year, and all-cause mortality in chronic immunemediated inflammatory disease managed in UK general practice. Rheumatology (Oxf) 2009; 48: 78 82.
35. Cosnes J, Beaugerie L, Carbonnel F et al. Smoking cessation and the course of Crohn's disease: An intervention study. Gastroenterology 2001; 120: 1093 1099.
36. Cosnes J, Carbonnel F, Beaugerie L et al. Effects of cigarette smoking on the long-Term course of Crohn's disease. Gastroenterology 1996; 110: 424 431.
37. Song XM, Gao X, Li MZ et al. Clinical features and risk factors for primary surgery in 205 patients with Crohn's disease: Analysis of a South China cohort. Dis Colon Rectum 2011; 54: 1147 1154.
38. Picco MF, Bayless TM. Tobacco consumption and disease duration are associated with fistulizing and stricturing behaviors in the first 8 years of Crohn's disease. Am J Gastroenterol 2003; 98: 363 368.
39. Lazarev M, Huang C, Bitton A et al. Relationship between proximal Crohn's disease location and disease behavior and surgery: A cross-sectional study of the IBD Genetics Consortium. Am J Gastroenterol 2013; 108: 106 112.
40. Services USDoHaH.The Health Consequences of Smoking-50 Years of Progress. National Library of Medicine: Rockville, MD, 2014.
41. Ueno A, Jijon H, Traves S et al. Opposing effects of smoking in ulcerative colitis and Crohn's disease may be explained by differential effects on dendritic cells. Inflamm Bowel Dis 2014; 20: 800 810.
42. Cope GF, Heatley RV, Kelleher JK. Smoking and colonic mucus in ulcerative colitis. Br Med J (Clin Res Ed) 1986; 293: 481.
43. Roifman I, Sun YC, Fedwick JP et al. Evidence of endothelial dysfunction in patients with inflammatory bowel disease. Clini Gastroenterol Hepatol 2009; 7: 175 182.
44. Benjamin JL, Hedin CR, Koutsoumpas A et al. Smokers with active Crohn's disease have a clinically relevant dysbiosis of the gastrointestinal microbiota. Inflamm Bowel Dis 2012; 18: 1092 1100.
45. Molodecky NA, Panaccione R, Ghosh S et al. Challenges associated with identifying the environmental determinants of the inflammatory bowel diseases. Inflamm Bowel Dis 2011;17:1792 1799.